Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$533.2m

Knight Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Knight Therapeutics has a total shareholder equity of CA$773.9M and total debt of CA$51.7M, which brings its debt-to-equity ratio to 6.7%. Its total assets and total liabilities are CA$962.3M and CA$188.4M respectively. Knight Therapeutics's EBIT is CA$10.3M making its interest coverage ratio 277.7. It has cash and short-term investments of CA$172.3M.

Key information

6.7%

Debt to equity ratio

CA$51.65m

Debt

Interest coverage ratio277.7x
CashCA$172.32m
EquityCA$773.91m
Total liabilitiesCA$188.39m
Total assetsCA$962.29m

Recent financial health updates

Recent updates

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 09
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Financial Position Analysis

Short Term Liabilities: GUD's short term assets (CA$397.6M) exceed its short term liabilities (CA$118.2M).

Long Term Liabilities: GUD's short term assets (CA$397.6M) exceed its long term liabilities (CA$70.2M).


Debt to Equity History and Analysis

Debt Level: GUD has more cash than its total debt.

Reducing Debt: GUD's debt to equity ratio has increased from 0% to 6.7% over the past 5 years.

Debt Coverage: GUD's debt is well covered by operating cash flow (102.1%).

Interest Coverage: GUD's interest payments on its debt are well covered by EBIT (277.7x coverage).


Balance Sheet


Discover healthy companies